Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE10A | Q9Y233 | 13/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | GLA | P06280 | 1/20 | 0.39 |
| ▸ | TDO2 | P48775 | 1/20 | 0.38 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.38 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.37 |
| ▸ | KIT | P10721 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2593454 | 0.92 | PDE10A (0.47) | PDE10AGAAGLA | |
| SCHEMBL2596257 | 0.90 | PDE10A (0.49) | PDE10AGAAGLAHRH4 | |
| SCHEMBL2589986 | 0.89 | PDE10A (0.58) | PDE10A | |
| SCHEMBL2593456 | 0.89 | PDE10A (0.47) | PDE10AGAAGLA | |
| SCHEMBL2596049 | 0.88 | PDE10A (0.48) | PDE10AGAAGLAHRH4 | |
| SCHEMBL2596265 | 0.88 | PDE10A (0.48) | PDE10AGAAGLAHRH4 | |
| SCHEMBL2593448 | 0.86 | PDE10A (0.46) | PDE10AGAAGLAHRH4 | |
| SCHEMBL2589976 | 0.86 | PDE10A (0.46) | PDE10AGAAGLAHRH4 | |
| SCHEMBL9994735 | 0.85 | PDE10A (0.43) | PDE10AGAAGLAHRH4 | |
| SCHEMBL2596030 | 0.84 | POLB (0.46) | PDE10AGAAGLAKIT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8946230-B2 | Aryl- and heteroaryl- nitrogen-heterocyclic compounds as PDE10 inhibitors | AMGEN INC. (US) | 2015-02-03 | — | — | US | claimed |
| EP-2569299-A1 | NITROGEN- HETEROCYCLIC COMPOUNDS AS PHOSPHODIESTERASE 10 INHIBITORS | Amgen Inc. (US) | 2013-03-20 | — | — | EP | claimed |
| US-20110306590-A1 | ARYL- AND HETEROARYL- NITROGEN-HETEROCYCLIC COMPOUNDS AS PDE10 INHIBITORS | AMGEN INC. | 2011-12-15 | — | — | US | claimed |
| WO-2011143129-A1 | NITROGEN- HETEROCYCLIC COMPOUNDS AS PHOSPHODIESTERASE 10 INHIBITORS | AMGEN INC. (US) | 2011-11-17 | — | — | WO | claimed |
| US-8946230-B2 | Aryl- and heteroaryl- nitrogen-heterocyclic compounds as PDE10 inhibitors | AMGEN INC. (US) | 2015-02-03 | — | — | US | disclosed |
| US-8946230-B2 | Aryl- and heteroaryl- nitrogen-heterocyclic compounds as PDE10 inhibitors | AMGEN INC. (US) | 2015-02-03 | — | — | US | disclosed |
| US-8946230-B2 | Aryl- and heteroaryl- nitrogen-heterocyclic compounds as PDE10 inhibitors | AMGEN INC. (US) | 2015-02-03 | — | — | US | disclosed |
| EP-2569299-A1 | NITROGEN- HETEROCYCLIC COMPOUNDS AS PHOSPHODIESTERASE 10 INHIBITORS | Amgen Inc. (US) | 2013-03-20 | — | — | EP | disclosed |
| US-20110306590-A1 | ARYL- AND HETEROARYL- NITROGEN-HETEROCYCLIC COMPOUNDS AS PDE10 INHIBITORS | AMGEN INC. | 2011-12-15 | — | — | US | disclosed |
| US-20110306590-A1 | ARYL- AND HETEROARYL- NITROGEN-HETEROCYCLIC COMPOUNDS AS PDE10 INHIBITORS | AMGEN INC. | 2011-12-15 | — | — | US | disclosed |
| US-20110306590-A1 | ARYL- AND HETEROARYL- NITROGEN-HETEROCYCLIC COMPOUNDS AS PDE10 INHIBITORS | AMGEN INC. | 2011-12-15 | — | — | US | disclosed |
| WO-2011143129-A1 | NITROGEN- HETEROCYCLIC COMPOUNDS AS PHOSPHODIESTERASE 10 INHIBITORS | AMGEN INC. (US) | 2011-11-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110306590-A1 | ARYL- AND HETEROARYL- NITROGEN-HETEROCYCLIC COMPOUNDS AS PDE10 INHIBITORS | HDAC10, PDE10A, PDE9A | PDE10A 2/4885GAA 194/4885GLA 1689/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.